

Retraction to 10.1177/1758835920922055

Ther Adv Med Oncol

2023, Vol. 15: 1

DOI: 10.1177/
17588359231172420

© The Author(s), 2023.
Article reuse guidelines:
[sagepub.com/journals-
permissions](https://sagepub.com/journals-permissions)

The following article has been retracted at the request of the Editor and Publisher:

Feng W, Dean DC, Hornicek FJ, et al. Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma. *Therapeutic Advances in Medical Oncology*. 2020;12. doi:10.1177/1758835920922055.

The authors contacted SAGE Publishing to replace Figure 2 in this publication. The Journal Editor noted a PubPeer post that highlighted duplicated features within individual panels of Figure 2A.

An internal investigation of the remaining figures raised concerns in the following figure panels:

- A) Figure 1A Myc and β -actin panel
- B) Figure 1B Myc and β -actin panel
- C) Figure 5C KHOS Myc and β -actin panel and U2OS Myc and β -actin panel
- D) Figure 6C KHOS Myc and β -actin panel and U2OS Myc and β -actin panel

The authors explained the errors in Figure 2 were inadvertent and provided underlying images for all the figures cited above. An internal examination of these images raised further concerns about the integrity of the figure panels.

Due to unresolved concerns about image integrity that call into question the validity of the findings, the *Therapeutic Advances in Medical Oncology* Editor retracts the article.

Authors disagreed with the retraction.